New Ray Medicine International Holding Limited (HKG:6108)

HKG:6108 Revenue

New Ray Medicine International Holding had revenue of 113.42M HKD in the half year ending June 30, 2026, with 578.43% growth. This brings the company's total for the last twelve months to 199.09M, up 63.29% year-over-year. In the year 2025, New Ray Medicine International Holding had annual revenue of 130.37M with 38.78% growth. That makes New Ray Medicine International Holding the 32,381st largest company in the world by revenue and 1,945th in Hong Kong.

• Revenue (ttm): 199.09M
• Revenue Growth: +63.29%
• P/S Ratio: 0.26
• Revenue / Employee: n/a
• Employees: 31
• Market Cap: 52.16M

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Distribution and Trading of Pharmaceutical Products 127.93M 98.1%
• Provision of Marketing and Promotion Services of Drugs 2.44M 1.9%

Fiscal year ended Dec 31, 2025 See the full HKG:6108 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	130.37M	36.43M	38.78%
Dec 31, 2024	93.95M	43.79M	87.31%
Dec 31, 2023	50.15M	-39.62M	-44.13%
Dec 31, 2022	89.77M	-245.61M	-73.23%
Dec 31, 2021	335.38M	202.17M	151.76%

Data Source: S&P Global Market Intelligence Last updated: Sep 16, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 22, 2026

Data Sources Report a data error